Class / Patent application number | Description | Number of patent applications / Date published |
536112000 | Dextran or derivative | 10 |
20100324281 | BIOSENSOR AND METHOD FOR IMMOBILIZING A PHYSIOLOGICALLY ACTIVE SUBSTANCE - An object of the present invention is to provide a biosensor and a method for immobilizing a physiologically active substance, by which preconcentration effects can be obtained at a pH that is equivalent to or higher than the isoelectric point of the physiologically active substance and the physiologically active substance can be covalently bound to the surface. The present invention provides a biosensor comprising a solid substrate to which a polymer having a primary or secondary amino group is bound, by which a physiologically active substance can be chemically immobilized following preconcentration of the substance at a pH that is equivalent to or higher than the isoelectric point of the substance. | 12-23-2010 |
20110263842 | DEXTRAN FOR TREATING LUNG CANCER - Dextran for preparing medicine for anti-lung cancer, has repeated structure unit and molecular weight of 1.5-2.5 million Daltons. The dextran is extracted from land slug. | 10-27-2011 |
20120309956 | MICROPROCESSING FOR PREPARING A POLYCONDENSATE - The present invention relates to a process for preparing polydextrose by using a microdevice. It further relates to the use of a microdevice for the polycondesation reactions. | 12-06-2012 |
20140005379 | NANOPARTICLE DELIVERY SYSTEM AND COMPONENTS THEREOF | 01-02-2014 |
20140142294 | METHOD FOR MANUFACTURE OF DEXTRAN, DEXTRAN SOLUTION OBTAINED, AND USES - Microbiological method of production of a dextran solution, according to which a culture medium containing sucrose is inoculated with a preculture of a bacterial strain that is able to produce dextran, then the dextran solution obtained at the end of fermentation is recovered directly, without a subsequent concentration step, characterized in that:—before inoculation, the culture medium contains at least 10 wt. % of sucrose,—after inoculation, sucrose is added again in conditions such that the total amount of sucrose in the medium, including that present before inoculation, is at least 16 wt. %,—the dextran solution obtained contains at least 10 wt. % of dextran. The native solution of dextran obtained and use of the solution as a flocculant. | 05-22-2014 |
20140303364 | STABLE IRON OLIGOSACCHARIDE COMPOUND - The invention relates to an iron oligosaccharide compound with improved stability comprising a hydrogenated oligosaccharide in stable association with ferric oxyhydroxide, the content of dimer saccharide in said hydrogenated oligosaccharide being 2.9% by weight or less, based on the total weight of the hydrogenated oligosaccharide. In further aspects is provided a process for preparing said compound as well as the use of said compound for preparation of a composition for treatment of iron deficiency anaemia. | 10-09-2014 |
20140364598 | STABLE IRON OLIGOSACCHARIDE COMPOUND - The invention relates to an iron oligosaccharide compound with improved stability comprising a hydrogenated oligosaccharide in stable association with ferric oxyhydroxide, the content of dimer saccharide in said hydrogenated oligosaccharide being 2.9% by weight or less, based on the total weight of the hydrogenated oligosaccharide. In further aspects is provided a process for preparing said compound as well as the use of said compound for preparation of a composition for treatment of iron deficiency anaemia. | 12-11-2014 |
20180022834 | OXIDIZED DEXTRAN | 01-25-2018 |
536113000 | Iron containing | 2 |
20140296508 | PROCESS FOR THE PREPARATION OF TRIVALENT IRON COMPLEXES WITH MONO-, DI- AND POLYSACCHARIDE SUGARDS - Process for the preparation of trivalent iron complexes with mono-, di- and polysaccharide sugars, consisting of the activation of the sugar by oxidation with nascent bromine generated in situ by reaction between an alkaline or alkaline earth bromine and an alkaline hypochlorite, the complexation of the activated sugar in solution with a ferric salt dissolved in an aqueous solution, the purification of the resulting solution through ultrafiltration and finally the stabilization of the trivalent iron-sugar complex by heating at a temperature between 60° C. and 100° C. for a period between 1 and 4 hours at a pH between 9.0 and 11.0. | 10-02-2014 |
20140296509 | Polyol and Polyether Iron Oxide Complexes as Pharmacological and/or MRI Contrast Agents - Iron oxide complexes, pharmacological compositions and unit dosage thereof, and methods for their administration, of the type employing an iron oxide complex with a polyol, are disclosed. The pharmacological compositions employ a polysaccharide iron oxide complex, wherein the polysaccharide is a modified polyol such as a carboxyalkylated reduced dextran. The complex is stable to terminal sterilization by autoclaving. The compositions are suitable for parenteral administration to a subject for the treatment of iron deficiencies or as MRI contrast agent. The complex is substantially immunosilent, provide minimal anaphylaxis and undergo minimal dissolution in vivo. The pharmacological compositions of the complex contain minimal free iron which can be quantified by a variety of methods. | 10-02-2014 |